Shareholder Information

On 19 November 2012, Amsterdam Molecular Therapeutics (AMT) Holding N.V. delisted from NYSE Euronext in Amsterdam and the company and its shares ceased to exist.

 

Extraordinary Annual General Meeting 2012 Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Provides Publication of the minutes of the Extraordinary Annual General Meeting held on 30th March 2012. Download Minutes

 

Annual General Meeting 2012 Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting. Amsterdam, The Netherlands – July 13, 2012 – Amsterdam Molecular Therapeutics (AMT) Holding NV (in liquidation) (Euronext: AMT) published its Annual Report and Accounts for the year ended December 31, 2011 and announced that it will host its Annual General Meeting at its headquarters (Meibergdreef 61, 1105 BA Amsterdam Zuidoost, the Netherlands) at 14.00 hrs on September 12, 2012. Shareholders of the dissolved company are invited to attend. Press release EN Download Notice and Agenda Download Explanatory Notes Download Proxy and Voting Instructions Download 2011 Annual Report Download AGM Voting Results

 

Notice to holders of Depositary Receipts of ordinary shares B in uniQure B.V. issued by Stichting Administratiekantoor uniQure B.V. (ISIN NL 0010124913) Bericht aan houders van certificaten van aandelen B in uniQure B.V. uitgegeven door Stichting Administratiekantoor uniQure B.V. (ISIN NL0010124913) Download Notice En Download Notice NL Download Registration Form En Download Registration Form NL Download uniQure BV Technical Information Memorandum

 

Overview of key transaction elements and timetable with regard to the public-to-private and financing transaction between Click here to download PDF

 

Explanatory note to Constitutional Documents Articles of Association UniQure Articles of Association Stichting Administratiekantoor Determination trust conditions

Amsterdam Molecular Therapeutics Summary and Q&A of the Shareholder Information Meetings on 23 February and 20 March, 2012 Download Summary

Proxy and Instruction to Vote for the EGM to be held on 30 March 2012 A shareholder who chooses to have himself represented at the Extraordinary General Meeting by a third party must provide AMT with a proxy to that effect. For the granting of a proxy, shareholders are required to use the form, which can be obtained here or via Aicha Diba, telephone number: +31 (0)20 5668014; telefax number: +31 (0)20 5669272. The completed form, duly completed by the shareholder, must have been received by AMT by 15:00 CET on 27 March 2012 ultimately. Receipt of proxy forms can be rejected after this time deadline. Participation in the meeting can be made dependant on identification of the participants. Download Proxy form

Shareholder Information Meeting 20 March 2012 In conjunction with the announcement on Friday February 17, 2012 of AMT’s Business being acquired by uniQure BV,  we are  pleased to invite you to our company on March 20, 2012 from 17.00 – 19.00  at AMT, 61 Meibergdreef in Amsterdam for an informational meeting on the  transaction. During this meeting, Ferdinand Verdonck head of the  Special Committee for the evaluation of the transaction, Jörn Aldag (CEO),  Piers Morgan (CFO) Dr. Carlos Camozzi (Chief Medical Officer) will be on hand  to answer investor questions. You can sign up for this meeting by sending  an e-mail to amtir@amtbiopharma.com For this meeting we have a maximum  capacity of 30 people, so if you want to attend this meeting, it is necessary  to register a.s.a.p. For questions or more information please contact Aicha  Diba on the aforementioned e-mail or telephone +31 20 566 80  14. Uitnodiging informatiebijeenkomst AMT – 23  Februari Naar aanleiding van de op 17 februari  aangekondigde acquisitie door uniQure BV van AMT, nodigen wij u graag uit voor  een informatieve bijeenkomst op 20 maart a.s. van 17.00 – 19.00 uur  bij AMT aan de Meibergdreef 61 te Amsterdam. Tijdens deze bijeenkomst  zullen Ferdinand Verdonck, voorzitter van het Speciale Comité , Jörn Aldag  (CEO), Piers Morgan (CFO),  Dr. Carlos Camozzi (Chief Medical Officer) na  een korte presentatie vragen van investeerders beantwoorden. U kunt zich  voor deze bijeenkomst aanmelden door een e-mail te sturen naar amtir@amtbiopharma.comEr zijn voor deze bijeenkomst maximaal 30 plaatsen  beschikbaar. Indien u bij deze meeting aanwezig wilt zijn is het dus  noodzakelijk uzelf tijdig in te schrijven. Voor vragen of meer informatie  kunt u contact opnemen met Aicha Diba via eerder genoemd e-mailadres of  telefoonnummer 020 - 566 80 14

Shareholder Information Meeting 23 February 2012 In conjunction with the announcement on Friday  February 17, 2012 of AMT’s Business being acquired by uniQure BV,  we are  pleased to invite you to our company on February 23, 2012 from 11.00 – 13:00  at AMT, 61 Meibergdreef in Amsterdam for an informational meeting on the  transaction. The presentation is available to download here The minutes of the shareholder information meeting are available to download here

Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV Amsterdam, The Netherlands – February 17, 2012 – Amsterdam Molecular Therapeutics (Euronext: AMT) announced today that its board of directors is recommending a substantial corporate restructuring and financing transaction which, if approved by shareholders, will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV, and the AMT legal entity being liquidated and delisted. Shareholder Circular Extraordinary Shareholder Meeting called to vote on the Transaction. Notice of EGM Explanatory Notes Press Release EN Press Release NL Voting Results EGM

Annual General Meeting 2011 Organized by Amsterdam Molecular Therapeutics (AMT) Holding N.V., having its address at Meibergdreef 61, 1105 BA Amsterdam Zuidoost, the Netherlands, on May 3, 2011, at 14.00 hours. On the date of the notice for this meeting, the company had 23,512,225 shares issued, each representing one vote. AGM Notice Explanatory Notes AGM Amendment Articles of Association (English) Amendment Articles of Association (Dutch) Proxy Form AGM Voting Results Minutes of AGM

October 2010 Private Placement Information October 5, 2010 Not for release, publication or distribution in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Japan or South Africa or to US persons. This announcement is not a prospectus and is not an offer for sale of securities in the United States, Canada, South Africa, Australia, Japan or any other jurisdiction. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) announces October 5, 2010 the launch of an equity offering by means of a private placement. Underneath the prospectus, press releases and other relevant information. Press Release, Result of the Equity Offering Pricing Statement Press Release, Launch of the Equity Offering Prospectus H1 2010 Results Anual Report 2009 Anual Report 2008 Anual Report 2007 Articles of Association Statuten

 

Financial Calendar 2011

Q1 Business Update
May 19, 2011

Half Year Results
August 25, 2011

Q3 Business Update
November 17, 2011

Full Year Results 2011
April 26, 2012

DISCLAIMER – IMPORTANT

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBPAGE BY AMSTERDAM MOLECULAR THERAPEUTICS (AMT) HOLDING N.V. IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE MATERIALS CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

Please read this notice carefully - it applies to all persons who view this webpage. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the site.

Non-Dutch persons

Viewing the materials made available on this website may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to access such materials. Any person resident outside the Netherlands who wishes to access these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

The materials made available on this website do not contain, constitute or form part of, and should not be construed as, an offer, or the invitation or solicitation to subscribe for or purchase any securities ("Securities") mentioned in the materials and nothing contained herein shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

The Securities have not been (nor will be) registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

No Securities will be offered or allotted directly or indirectly into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States, unless an exemption from registration under the US Securities Act, is available. This includes, but is not limited to, facsimile transmission, electronic mail, telephone and the internet. Accordingly, copies of materials made available on this website and any related documents will not and must not be mailed or otherwise transmitted, distributed or forwarded in or into the United States.

The materials contained herein have not been submitted to or reviewed by the US Securities and Exchange Commission (the "SEC") or any state securities commission of any other jurisdiction, and neither the SEC nor any such state securities commission of any other jurisdiction has (a) approved or disapproved, (b) passed upon the merits or fairness of, or (c) passed upon the adequacy or accuracy of the disclosure of any materials contained herein. Any representation to the contrary is a criminal offence in the United States.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to these materials is being made available on this webpage by Amsterdam Molecular Therapeutics (AMT) Holding N.V. in good faith and for information purposes only. Any person seeking access to this webpage represents and warrants to Amsterdam Molecular Therapeutics (AMT) Holding N.V. that they are doing so for information purposes only.

Neither any press announcement nor any other document made available on this website constitutes an offer to sell, an invitation to induce an offer or the solicitation of an offer to acquire, Securities in Amsterdam Molecular Therapeutics (AMT) Holding N.V. or Kairos Therapeutics B.V. and cannot be relied upon for any investment contract or decision. Furthermore, such documents do not constitute a recommendation by Amsterdam Molecular Therapeutics (AMT) Holding N.V. or any other party to sell or buy Securities.

Unless otherwise determined by Amsterdam Molecular Therapeutics (AMT) Holding N.V. and permitted by applicable law and regulation, copies of the contents of the following pages (including documents posted thereon) are not being, and must not be, released or otherwise forwarded, distributed or sent in or into the United States or any other jurisdiction where their extension or availability (and/or any transaction contemplated thereby) would breach any applicable law, and persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into the United States or any other jurisdiction where to do so would breach any applicable law.

Confirmation of understanding and acceptance of disclaimer

I certify that I am not located in the United States or any other jurisdiction where the release, publication or distribution of these materials would be unlawful.

I have read and understood the disclaimer set out above and agree to be bound by its terms.

I confirm that I am permitted under applicable law and regulation to proceed to the electronic versions of these materials and receive information of the kind contained in this website.

DISCLAIMER – IMPORTANT

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBPAGE BY AMSTERDAM MOLECULAR THERAPEUTICS (AMT) HOLDING N.V. IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE MATERIALS CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

Please read this notice carefully - it applies to all persons who view this webpage. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the site.

Non-Dutch persons

Viewing the materials made available on this website may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to access such materials. Any person resident outside the Netherlands who wishes to access these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

The materials made available on this website do not contain, constitute or form part of, and should not be construed as, an offer, or the invitation or solicitation to subscribe for or purchase any securities ("Securities") mentioned in the materials and nothing contained herein shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

The Securities have not been (nor will be) registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

No Securities will be offered or allotted directly or indirectly into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States, unless an exemption from registration under the US Securities Act, is available. This includes, but is not limited to, facsimile transmission, electronic mail, telephone and the internet. Accordingly, copies of materials made available on this website and any related documents will not and must not be mailed or otherwise transmitted, distributed or forwarded in or into the United States.

The materials contained herein have not been submitted to or reviewed by the US Securities and Exchange Commission (the "SEC") or any state securities commission of any other jurisdiction, and neither the SEC nor any such state securities commission of any other jurisdiction has (a) approved or disapproved, (b) passed upon the merits or fairness of, or (c) passed upon the adequacy or accuracy of the disclosure of any materials contained herein. Any representation to the contrary is a criminal offence in the United States.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access

Access to these materials is being made available on this webpage by Amsterdam Molecular Therapeutics (AMT) Holding N.V. in good faith and for information purposes only. Any person seeking access to this webpage represents and warrants to Amsterdam Molecular Therapeutics (AMT) Holding N.V. that they are doing so for information purposes only.

Neither any press announcement nor any other document made available on this website constitutes an offer to sell, an invitation to induce an offer or the solicitation of an offer to acquire, Securities in Amsterdam Molecular Therapeutics (AMT) Holding N.V. or Kairos Therapeutics B.V. and cannot be relied upon for any investment contract or decision. Furthermore, such documents do not constitute a recommendation by Amsterdam Molecular Therapeutics (AMT) Holding N.V. or any other party to sell or buy Securities.

Unless otherwise determined by Amsterdam Molecular Therapeutics (AMT) Holding N.V. and permitted by applicable law and regulation, copies of the contents of the following pages (including documents posted thereon) are not being, and must not be, released or otherwise forwarded, distributed or sent in or into the United States or any other jurisdiction where their extension or availability (and/or any transaction contemplated thereby) would breach any applicable law, and persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into the United States or any other jurisdiction where to do so would breach any applicable law.

Confirmation of understanding and acceptance of disclaimer

I certify that I am not located in the United States or any other jurisdiction where the release, publication or distribution of these materials would be unlawful.

I have read and understood the disclaimer set out above and agree to be bound by its terms.

I confirm that I am permitted under applicable law and regulation to proceed to the electronic versions of these materials and receive information of the kind contained in this website.